Literature DB >> 16530769

The epidemiology of Lp-PLA(2): distribution and correlation with cardiovascular risk factors in a population-based cohort.

Margaretha Persson1, Jan-Ake Nilsson, Jeanenne J Nelson, Bo Hedblad, Göran Berglund.   

Abstract

Lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) is an enzyme that is produced by inflammatory cells (macrophages, T-lymphocytes and mast cells) and hydrolyzes oxidized phospholipids in LDL. Several epidemiology studies indicate that Lp-PLA(2) appears to be an independent marker of cardiovascular risk. This study was conducted to define the distribution of Lp-PLA(2) in a large population-based cohort and to determine associations between Lp-PLA(2) and other risk factors for CVD. The study group consisted of participants from the Malmö Diet and Cancer study (1992-1994). Lp-PLA(2) (activity and mass) was measured from samples obtained at baseline for 5402 participants (3167 women). A strong correlation was observed between Lp-PLA(2) activity and mass in this study (r=0.57). Highest correlations were observed between Lp-PLA(2) activity and LDL (r=0.45) and LDL/HDL ratio (r=0.54) and a strong inverse correlation to HDL (r=-0.31). The correlations between Lp-PLA(2) mass and lipids were not as strong as the correlation between activity and lipids. Lp-PLA(2) activity and mass were correlated with increased ultrasound determined carotid intima-media thickness. We conclude that Lp-PLA(2) is strongly correlated with several cardiovascular risk factors, especially lipid fractions, and with the degree of carotid artery atherosclerosis. However, the measured variables accounted for only 19% and 35% of the variation in Lp-PLA(2) mass and activity respectively.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16530769     DOI: 10.1016/j.atherosclerosis.2006.02.016

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  35 in total

1.  Genotype-by-diet effects on co-variation in Lp-PLA2 activity and LDL-cholesterol concentration in baboons fed an atherogenic diet.

Authors:  Amanda Vinson; Michael C Mahaney; Vince P Diego; Laura A Cox; Jeffrey Rogers; John L VandeBerg; David L Rainwater
Journal:  J Lipid Res       Date:  2008-03-11       Impact factor: 5.922

2.  Lipoprotein-associated phospholipase A2 and risk of incident cardiovascular disease in a multi-ethnic cohort: The multi ethnic study of atherosclerosis.

Authors:  Parveen K Garg; Robyn L McClelland; Nancy S Jenny; Michael H Criqui; Philip Greenland; Robert S Rosenson; David S Siscovick; Neal Jorgensen; Mary Cushman
Journal:  Atherosclerosis       Date:  2015-05-16       Impact factor: 5.162

3.  Circulating Lp-PLA₂ activity correlates with oxidative stress and cytokines in overweight/obese postmenopausal women not using hormone replacement therapy.

Authors:  Jean Kyung Paik; Minkyung Kim; Minjoo Kim; Yuna Yen; Hyeon Yeong Ahn; Sang-Hyun Lee; Jong Ho Lee
Journal:  Age (Dordr)       Date:  2015

4.  Elevated plasma platelet activating factor, platelet activating factor acetylhydrolase levels and risk of coronary heart disease or blood stasis syndrome of coronary heart disease in Chinese: a case control study: a case-control study.

Authors:  Guo-Hua Zheng; Shang-Quan Xiong; Li-Juan Mei; Hai-Ying Chen; Ting Wang; Jian-Feng Chu
Journal:  Inflammation       Date:  2012-08       Impact factor: 4.092

5.  Translational studies of lipoprotein-associated phospholipase A₂ in inflammation and atherosclerosis.

Authors:  Jane F Ferguson; Christine C Hinkle; Nehal N Mehta; Roshanak Bagheri; Stephanie L Derohannessian; Rhia Shah; Megan I Mucksavage; Jonathan P Bradfield; Hakon Hakonarson; Xuexia Wang; Stephen R Master; Daniel J Rader; Mingyao Li; Muredach P Reilly
Journal:  J Am Coll Cardiol       Date:  2012-02-21       Impact factor: 24.094

6.  Interaction between nonsynonymous polymorphisms in PLA2G7 gene and smoking on the risk of coronary heart disease in a Chinese population.

Authors:  Yunpeng Chi; Conghong Shi; Xiaojiang Zhang; Yang Xi
Journal:  J Thromb Thrombolysis       Date:  2018-07       Impact factor: 2.300

7.  Therapeutic Options to Reduce Lp-PLA2 Levels and the Potential Impact on Vascular Risk Reduction.

Authors:  Koto Ishida; Brett Cucchiara
Journal:  Curr Treat Options Cardiovasc Med       Date:  2013-06

8.  Genome-wide association study of Lp-PLA(2) activity and mass in the Framingham Heart Study.

Authors:  Sunil Suchindran; David Rivedal; John R Guyton; Tom Milledge; Xiaoyi Gao; Ashlee Benjamin; Jennifer Rowell; Geoffrey S Ginsburg; Jeanette J McCarthy
Journal:  PLoS Genet       Date:  2010-04-29       Impact factor: 5.917

9.  Plasma lipoprotein-associated phospholipase A2 levels in heart failure: association with mortality in the community.

Authors:  Yariv Gerber; Shannon M Dunlay; Allan S Jaffe; Joseph P McConnell; Susan A Weston; Jill M Killian; Véronique L Roger
Journal:  Atherosclerosis       Date:  2008-08-07       Impact factor: 5.162

10.  Lipoprotein-associated phospholipase A2 (Lp-PLA2) activity, platelet-activating factor acetylhydrolase (PAF-AH) in leukocytes and body composition in healthy adults.

Authors:  Paraskevi Detopoulou; Tzortzis Nomikos; Elizabeth Fragopoulou; Demosthenis B Panagiotakos; Christos Pitsavos; Christodoulos Stefanadis; Smaragdi Antonopoulou
Journal:  Lipids Health Dis       Date:  2009-06-05       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.